## Klaus Klumpp

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4707650/publications.pdf Version: 2024-02-01



KINIS KIIIMDD

#	Article	IF	CITATIONS
1	Antiviral Activity, Safety, and Pharmacokinetics of Capsid Assembly Modulator NVR 3-778 in Patients with Chronic HBV Infection. Gastroenterology, 2019, 156, 1392-1403.e7.	1.3	115
2	Preclinical Characterization of NVR 3-778, a First-in-Class Capsid Assembly Modulator against Hepatitis B Virus. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	45
3	Efficacy of NVR 3-778, Alone and In Combination With Pegylated Interferon, vs Entecavir In uPA/SCID Mice With Humanized Livers and HBV Infection. Gastroenterology, 2018, 154, 652-662.e8.	1.3	82
4	Hepatitis B Virus Capsid Assembly Modulators, but Not Nucleoside Analogs, Inhibit the Production of Extracellular Pregenomic RNA and Spliced RNA Variants. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	74
5	High-resolution crystal structure of a hepatitis B virus replication inhibitor bound to the viral core protein. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 15196-15201.	7.1	126
6	Capsid proteins of enveloped viruses as antiviral drug targets. Current Opinion in Virology, 2014, 5, 63-71.	5.4	43
7	Immune cell responses are not required to induce substantial hepatitis B virus antigen decline during pegylated interferon-alpha administration. Journal of Hepatology, 2014, 60, 500-507.	3.7	68